GWM
MRNA icon

Geneos Wealth Management’s Moderna MRNA Stock Holding History

Geneos Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$26.1K Buy
372
+226
+155% +$11.7K ﹤0.01% 1713
2026
Q1 		$7.42K Hold
146
– – ﹤0.01% 2071
2025
Q4 		$4.31K Hold
146
– – ﹤0.01% 2180
2025
Q3 		$3.77K Buy
146
+14
+11% +$391 ﹤0.01% 2207
2025
Q2 		$3.64K Sell
132
-53
-29% -$1.4K ﹤0.01% 2661
2025
Q1 		$5.25K Sell
185
-697
-79% -$24.7K ﹤0.01% 2503
2024
Q4 		$36.7K Sell
882
-1,212
-58% -$57.9K ﹤0.01% 1443
2024
Q3 		$140K Buy
2,094
+770
+58% +$70.7K 0.01% 866
2024
Q2 		$157K Hold
1,324
– – 0.01% 759
2024
Q1 		$141K Sell
1,324
-395
-23% -$39.8K 0.01% 778
2023
Q4 		$171K Sell
1,719
-284
-14% -$23.9K 0.01% 710
2023
Q3 		$207K Buy
2,003
+432
+27% +$48.2K 0.01% 676
2023
Q2 		$191K Buy
1,571
+50
+3% +$6.67K 0.01% 694
2023
Q1 		$234K Sell
1,521
-50
-3% -$8.25K 0.01% 620
2022
Q4 		$282K Sell
1,571
-444
-22% -$72.6K 0.02% 545
2022
Q3 		$238K Sell
2,015
-3,175
-61% -$482K 0.02% 556
2022
Q2 		$778K Sell
5,190
-5
-0.1% -$715 0.04% 392
2022
Q1 		$894K Buy
5,195
+16
+0.3% +$2.69K 0.04% 384
2021
Q4 		$1.31M Buy
5,179
+166
+3% +$48.5K 0.05% 330
2021
Q3 		$1.71M Hold
5,013
– – 0.07% 270
2021
Q2 		$1.17M Sell
5,013
-467
-9% -$83.5K 0.05% 324
2021
Q1 		$988K Sell
5,480
-1,550
-22% -$225K 0.03% 426
2020
Q4 		$863K Buy
7,030
+2,759
+65% +$279K 0.03% 392
2020
Q3 		$296K Buy
4,271
+431
+11% +$30.1K 0.02% 567
2020
Q2 		$235K Buy
3,840
+1,207
+46% +$66.1K 0.01% 620
2020
Q1 		$79K Buy
+2,633
New +$60.6K 0.01% 927

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Geneos Wealth Management's MRNA Position: Q2 2026 in Review

Geneos Wealth Management increased its Moderna (MRNA) stake by 155% in Q2 2026, buying an estimated $11.7K and bringing the position to 372 shares worth $26.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1713.

Geneos Wealth Management first reported a position in MRNA in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.71M in Q3 2021. 783 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Geneos Wealth Management held 372 shares of Moderna worth $26.1K as of Q2 2026.
  • Geneos Wealth Management bought 226 Moderna shares in Q2 2026, an estimated $11.7K.
  • Moderna made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1713 holding.
  • Geneos Wealth Management first reported a position in Moderna in Q1 2020 and has held it in 26 quarters since.
  • Geneos Wealth Management's Moderna position peaked at $1.71M in Q3 2021.
  • 783 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.